Exchange: NASDAQ·Updated 09:10 PM EST

PACB News

News
all
press releases
Pacific Biosciences of California (PACB) Reports Q3 Loss, Beats Revenue Estimates
Pacific Biosciences (PACB) delivered earnings and revenue surprises of +15.39% and +7.16%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Pacific Biosciences of California (PACB) Reports Q3 Loss, Beats Revenue Estimates
Pacific Biosciences (PACB) delivered earnings and revenue surprises of +15.39% and +7.16%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
More News
Ark Invest increased its exposure to several widely followed biotechnology stocks during the session.
Stocktwits
In the latest trading session, Pacific Biosciences of California (PACB) closed at $2.9, marking a +2.47% move from the previous day.
Zacks
Glaukos (GKOS) delivered earnings and revenue surprises of +491.67% and +24.99%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
PACB's growing clinical adoption, advanced sequencing technologies and rising consumables sales support growth, but funding headwinds and margin pressures persist.
Zacks
Ark Invest reduced its exposure to several widely followed technology stocks during the session.
Stocktwits
The latest trading day saw Pacific Biosciences of California (PACB) settling at $2.06, representing a -3.74% change from its previous close.
Zacks
In the most recent trading session, Pacific Biosciences of California (PACB) closed at $1.99, indicating a -2.93% shift from the previous trading day.
Zacks
PACB partners with TychoBio to harness AI and long-read RNA sequencing for rare disease therapies, aiming to improve drug efficacy and safety through advanced data models.
Zacks
The latest trading day saw Pacific Biosciences of California (PACB) settling at $2.3, representing a -15.44% change from its previous close.
Zacks

Advertisement|Remove ads.